Intraductal Papillary Mucinous Neoplasm of the Pancreas: Understanding the Basics and Beyond.
| Autor: | Weissman S; Internal Medicine, Touro College of Osteopathic Medicine, New York, USA., Thaker R; Internal Medicine, Touro College of Osteopathic Medicine, New York, USA., Zeffren N; Internal Medicine, Hoboken University Medical Center, Hoboken, USA., Sarfaraz R; Internal Medicine, Bayonne Medical Center, Bayonne, USA., Dedousis J; Internal Medicine, Bayonne Medical Center, Bayonne, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2019 Jan 11; Vol. 11 (1), pp. e3867. Date of Electronic Publication: 2019 Jan 11. |
| DOI: | 10.7759/cureus.3867 |
| Abstrakt: | Intraductal papillary mucinous neoplasm (IPMN) is a benign cystic lesion that grows in the pancreatic ductal system. While the risk for undergoing malignant transformation is dependent on a number of factors, the risk is certainly present, differentiating it from other cystic lesions of the pancreas. Additionally, IMPN is to be starkly contrasted with adenocarcinoma of the pancreas, which is by nature malignant. There are numerous ways to detect IPMN, which is helpful, as a patient may be initially asymptomatic at presentation. Prognosis varies depending upon the malignant potential of the lesion at hand. Surgical resection is the mainstay of treatment in patients with a high probability of malignancy potential. What once was a very confusing diagnosis is now becoming defined based on new literature. The goal of this manuscript is to compile the literature on IPMNs in a clear and precise way as to educate clinicians as to the nature of this increasingly prevalent disease. Competing Interests: The authors have declared that no competing interests exist. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|